Oruka Therapeutics Financial Statements
NASDAQ: ORKAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
82.11+4.83 (+6.25%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Oruka Therapeutics revenue and earnings
Oruka Therapeutics reported a net loss of $105.4 million, compared with a loss of $5.3 million a year earlier.
Summary generated from market data by MetaCap's automated system. Methodology
Oruka Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 | FY 20152015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses | 122.05M | 7.30M | 10.60M | 19.34M | 9.77M | 5.81M | 8.12M | 18.71M | 16.61M | 11.46M |
| Research & Development | 100.64M | 1.01M | 4.75M | 13.83M | 4.99M | 1.83M | 4.24M | 14.08M | 12.35M | 7.06M |
| Operating Income | -122.05M | -7.30M | -10.60M | -19.34M | -9.77M | -5.81M | -8.12M | -18.71M | -16.61M | -11.46M |
| Interest Expense | — | — | — | — | 9.00K | 7.00K | 8.00K | 6.00K | — | 4.00K |
| Other Income (Expense) | 16.62M | — | — | — | — | — | — | — | — | — |
| Pretax Income | -105.43M | — | — | -19.32M | -9.75M | -5.65M | -7.96M | -18.55M | -16.44M | — |
| Income Tax | — | 0 | 0 | 0 | -9.00K | -167.00K | -31.00K | -61.00K | 0 | 0 |
| Net Income | -105.43M | -5.34M | -9.93M | -19.32M | -9.74M | -5.48M | -7.93M | -18.49M | -16.44M | -11.45M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | -0.37 | -0.69 | -1.39 | -2.07 | -4.15 | -10.31 | -1.77 | -1.81 | -1.82 |
| EPS (Diluted) | — | -0.37 | -0.69 | -1.39 | -2.07 | -4.15 | -10.31 | -1.77 | -1.81 | -1.82 |
| Shares Outstanding (Basic) | — | 14.42M | 14.41M | 13.90M | 4.71M | 1.32M | 769.39K | 10.43M | 9.07M | 6.29M |
| Shares Outstanding (Diluted) | — | 14.42M | 14.41M | 13.90M | 4.71M | 1.32M | 769.39K | 10.43M | 9.07M | 6.29M |
| EBITDA | -121.97M | -7.28M | -10.58M | -19.32M | -9.76M | -5.80M | -8.10M | -18.68M | -16.59M | -11.44M |
This table shows 10 annual periods of Oruka Therapeutics's income statement, from FY 2025 back to FY 2015, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow ORKA's reporting calendar. What is a income statement?